Clear Cell Renal Cell Carcinoma (CCRCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Clear cell renal cell carcinoma (CCRCC) is a renal cortical tumor characterized by malignant epithelial cells with clear cytoplasm and a compact-alveolar or acinar growth pattern accompanied by intricate vasculature. The disease may progress without noticeable symptoms in its early stage, but as it advances, symptoms such as hematuria, fatigue, fever, lump, flank pain, and weight loss may arise. Certain risk factors such as smoking, obesity, hypertension, kidney disease requiring dialysis, exposure to workplace toxins, and prolonged use of pain relievers can increase the chances of developing CCRCC. In some cases, CCRCC may cause blood clots in the renal vein of the affected kidney. The incidence rate of CCRCC increases with age, peaks in individuals aged 60 to 79, and is higher in males than females.
·
The overall incidence rate of ccRCC in the USA
was estimated to be 3.59 cases per 100,000 population.
Thelansis’s “Clear Cell Renal Cell
Carcinoma (CCRCC) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Clear Cell
Renal Cell Carcinoma (CCRCC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Clear Cell Renal Cell Carcinoma (CCRCC) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Clear Cell Renal Cell Carcinoma (CCRCC)
Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment